Cargando…
Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects
PURPOSE: Tenofovir amibufenamide (TMF) is a novel nucleotide reverse transcriptase inhibitor. The aim of this study was to investigate the effect of food on the single-dose pharmacokinetic properties of TMF. PATIENTS AND METHODS: In this open-label, randomized, crossover study, after an overnight fa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572397/ https://www.ncbi.nlm.nih.gov/pubmed/37840641 http://dx.doi.org/10.2147/DDDT.S419084 |
_version_ | 1785120225518157824 |
---|---|
author | Liu, Jian Wu, Minglan Kai, Jiejing Lin, Meihua Zheng, Yunliang Jiang, Yiya Huang, Qian Zhai, You Qiu, Yunqing |
author_facet | Liu, Jian Wu, Minglan Kai, Jiejing Lin, Meihua Zheng, Yunliang Jiang, Yiya Huang, Qian Zhai, You Qiu, Yunqing |
author_sort | Liu, Jian |
collection | PubMed |
description | PURPOSE: Tenofovir amibufenamide (TMF) is a novel nucleotide reverse transcriptase inhibitor. The aim of this study was to investigate the effect of food on the single-dose pharmacokinetic properties of TMF. PATIENTS AND METHODS: In this open-label, randomized, crossover study, after an overnight fast, eligible subjects received a single 25 mg dose of TMF tablet, either under fasted conditions or following consumption of a high-fat, high-calorie meal, followed by a two-week washout period. Blood samples were collected until 144 h after administration. TMF and its metabolite, tenofovir (TFV), were analyzed using validated liquid chromatography-tandem mass spectrometry methods. The geometric mean ratio (GMR) and the corresponding 90% confidence interval (CI) values of AUC(0–t), AUC(0–∞), and C(max) were acquired for analysis. The absence of an effect of food was indicated if the 90% CI values were within the predefined equivalence limits of 80%–125%. Safety and tolerability were also assessed. RESULTS: For TMF, adjusted GMR (90% CI) values for the fed versus fasted states were 150.28% (125.36%–180.16%), 158.24% (130.42%–192.00%), and 57.65% (45.68%–72.76%) for AUC(0–t), AUC(0–∞), and C(max), respectively. For TFV, the GMR (90% CI) of C(max) was 82.00% (74.30%–90.49%) after administration under fed conditions, slightly outside the bioequivalence boundary of 80%–125%, while the corresponding values for AUC(0–t) and AUC(0–∞) were within range. The absorption of TMF was delayed by food, with median T(max) values of 0.33 and 1.00 h in fasted and fed conditions, respectively. The adverse events observed in subjects were all mild. CONCLUSION: Our results demonstrated that TMF tablets were well-tolerated in healthy volunteers. When TMF tablets were taken with food, T(max) was delayed and exposures of TMF and TFV were higher than under fasted conditions. The modest changes observed are not considered clinically relevant, so TMF can be taken with or without food. |
format | Online Article Text |
id | pubmed-10572397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105723972023-10-14 Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects Liu, Jian Wu, Minglan Kai, Jiejing Lin, Meihua Zheng, Yunliang Jiang, Yiya Huang, Qian Zhai, You Qiu, Yunqing Drug Des Devel Ther Original Research PURPOSE: Tenofovir amibufenamide (TMF) is a novel nucleotide reverse transcriptase inhibitor. The aim of this study was to investigate the effect of food on the single-dose pharmacokinetic properties of TMF. PATIENTS AND METHODS: In this open-label, randomized, crossover study, after an overnight fast, eligible subjects received a single 25 mg dose of TMF tablet, either under fasted conditions or following consumption of a high-fat, high-calorie meal, followed by a two-week washout period. Blood samples were collected until 144 h after administration. TMF and its metabolite, tenofovir (TFV), were analyzed using validated liquid chromatography-tandem mass spectrometry methods. The geometric mean ratio (GMR) and the corresponding 90% confidence interval (CI) values of AUC(0–t), AUC(0–∞), and C(max) were acquired for analysis. The absence of an effect of food was indicated if the 90% CI values were within the predefined equivalence limits of 80%–125%. Safety and tolerability were also assessed. RESULTS: For TMF, adjusted GMR (90% CI) values for the fed versus fasted states were 150.28% (125.36%–180.16%), 158.24% (130.42%–192.00%), and 57.65% (45.68%–72.76%) for AUC(0–t), AUC(0–∞), and C(max), respectively. For TFV, the GMR (90% CI) of C(max) was 82.00% (74.30%–90.49%) after administration under fed conditions, slightly outside the bioequivalence boundary of 80%–125%, while the corresponding values for AUC(0–t) and AUC(0–∞) were within range. The absorption of TMF was delayed by food, with median T(max) values of 0.33 and 1.00 h in fasted and fed conditions, respectively. The adverse events observed in subjects were all mild. CONCLUSION: Our results demonstrated that TMF tablets were well-tolerated in healthy volunteers. When TMF tablets were taken with food, T(max) was delayed and exposures of TMF and TFV were higher than under fasted conditions. The modest changes observed are not considered clinically relevant, so TMF can be taken with or without food. Dove 2023-10-09 /pmc/articles/PMC10572397/ /pubmed/37840641 http://dx.doi.org/10.2147/DDDT.S419084 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, Jian Wu, Minglan Kai, Jiejing Lin, Meihua Zheng, Yunliang Jiang, Yiya Huang, Qian Zhai, You Qiu, Yunqing Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title | Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title_full | Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title_fullStr | Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title_full_unstemmed | Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title_short | Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects |
title_sort | effect of food on the pharmacokinetics of tenofovir amibufenamide: a phase i, randomized, open-label, two-period crossover trial in healthy adult subjects |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572397/ https://www.ncbi.nlm.nih.gov/pubmed/37840641 http://dx.doi.org/10.2147/DDDT.S419084 |
work_keys_str_mv | AT liujian effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT wuminglan effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT kaijiejing effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT linmeihua effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT zhengyunliang effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT jiangyiya effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT huangqian effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT zhaiyou effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects AT qiuyunqing effectoffoodonthepharmacokineticsoftenofoviramibufenamideaphaseirandomizedopenlabeltwoperiodcrossovertrialinhealthyadultsubjects |